Manuscript

Trade Press Services Releases White Paper

Retrieved on: 
Tuesday, March 26, 2024
Publishing, Book, Marketing, Research, Manuscript, Creativity

THOUSAND OAKS, Calif., March 26, 2024 /PRNewswire/ -- Trade Press Services, a leading provider of strategic marketing solutions, announces the release of its latest white paper, "Break into Publishing: What It Takes to Write, Produce, and Market Your Book." This comprehensive guide delves into the intricacies of the book publishing industry and offers valuable insights for aspiring authors seeking to navigate the journey from manuscript to publication.

Key Points: 
  • "Break into Publishing: What It Takes to Write, Produce, and Market Your Book"
    THOUSAND OAKS, Calif., March 26, 2024 /PRNewswire/ -- Trade Press Services, a leading provider of strategic marketing solutions, announces the release of its latest white paper, "Break into Publishing: What It Takes to Write, Produce, and Market Your Book."
  • Penned by seasoned industry experts, the white paper addresses the monumental investment of time, energy, and resources required to bring a book to fruition.
  • "Writing and publishing a book is the ultimate way for professionals to build authority and credibility in their marketplace," says Gerri Knilans, president of Trade Press Services.
  • This white paper provides aspiring authors with the information and guidance they need to research, write, publish, and market a book that can become their single greatest professional asset."

Researchers at Phoenix Children's First in the World to Produce Mouse Lungs in Rats

Retrieved on: 
Monday, March 25, 2024
Research, ESC, Bioreactor, B cell, Regeneration, Neurology, Rat, Cell, Osteogenesis imperfecta, Assistant, Cardiology, Critical Care Medicine (journal), Patient, American Journal, DNA, Pharmacist, Manuscript, Cancer, University, Hope, Doctor of Philosophy, Lung transplantation, MD, Biostatistics, Respiratory failure, Cas9, CRISPR, Stem cell, Premature, Research institute, College of Engineering (KNUST), Medicine, Nursing, Animal

PHOENIX, March 25, 2024 /PRNewswire/ -- Research conducted at the Phoenix Children's Research Institute at the University of Arizona College of Medicine — Phoenix reports the successful generation of a mouse lung in a rat, according to a paper published in the American Journal of Respiratory and Critical Care Medicine.

Key Points: 
  • The critical differentiating factor with this study is researchers incorporated CRISPR-Cas9, a unique genome editing technology that allows researchers to change genomes by altering sections of the DNA sequence.
  • Modifications of rat embryos by CRISPR-Cas9 allowed the formation of lung tissues consisting of almost all mouse lung cells.
  • This is one of many recent accolades for the Phoenix Children's Research Institute.
  • The Phoenix Children's Research Institute at the University of Arizona College of Medicine –Phoenix launched in May 2023, formalizing a longstanding research collaboration between the health system and the University of Arizona College of Medicine – Phoenix.

CKD Leaders Network Publishes New Thought Piece in Journal of Clinical Medicine

Retrieved on: 
Thursday, March 21, 2024
Research, Disease, FACC, Conditional sentence, TKG, Data science, CKD, Medicine, Patient, Author, Mortality, Manuscript, University, ICMJE, MPH, Network, Chronic kidney disease, Eli Lilly and Company, Multimedia, Marketing, Boehringer Ingelheim, Pharmaceutical industry

NEW YORK, March 21, 2024 /PRNewswire/ -- In support of National Kidney Month, CKD Leaders Network , a Kinetix Group Network of Excellence dedicated to defining and spreading a best practice model for population health-driven chronic kidney disease (CKD) management, announced its new manuscript in the Journal of Clinical Medicine.

Key Points: 
  • NEW YORK, March 21, 2024 /PRNewswire/ -- In support of National Kidney Month, CKD Leaders Network , a Kinetix Group Network of Excellence dedicated to defining and spreading a best practice model for population health-driven chronic kidney disease (CKD) management, announced its new manuscript in the Journal of Clinical Medicine.
  • "At The Kinetix Group, we are committed to improving care delivery through collaboration and innovation," said Anna Thomas , executive vice president.
  • CKD affects approximately 37 million individuals in the United States.
  • To learn more about CKD Leaders Network initiatives, contact [email protected] .

Mallinckrodt Announces Journal Publication of Real-World Data on Acthar® Gel (repository corticotropin injection) to Treat Symptomatic Sarcoidosis in African American and Non-African American Patients

Retrieved on: 
Monday, March 11, 2024
African Americans, Conference, Sarcoidosis, Disease, Adrenocorticotropic hormone (medication), Inflammation, Patient, Research, Manuscript, Adrenocorticotropic hormone, Respiratory disease, Therapy, FDA, Food, Pharmaceutical industry

DUBLIN, March 11, 2024 /PRNewswire/ -- Mallinckrodt plc, a global specialty pharmaceutical company, today announced the publication of findings from a retrospective chart review of Acthar® Gel (repository corticotropin injection) treatment outcomes for African American and non-African American patients with symptomatic sarcoidosis – including treatment patterns, co-medication use, and overall health outcomes.1 This analysis suggested that Acthar Gel treatment was associated with similar improvements in health outcomes, a reduction in symptoms, and reduced co-medication use in both African Americans and non-African Americans with symptomatic sarcoidosis.1 The manuscript was recently published online in Therapeutics & Clinical Risk Management.

Key Points: 
  • DUBLIN, March 11, 2024 /PRNewswire/ -- Mallinckrodt plc , a global specialty pharmaceutical company, today announced the publication of findings from a retrospective chart review of Acthar® Gel (repository corticotropin injection) treatment outcomes for African American and non-African American patients with symptomatic sarcoidosis – including treatment patterns, co-medication use, and overall health outcomes.1 This analysis suggested that Acthar Gel treatment was associated with similar improvements in health outcomes, a reduction in symptoms, and reduced co-medication use in both African Americans and non-African Americans with symptomatic sarcoidosis.1 The manuscript was recently published online in Therapeutics & Clinical Risk Management.
  • "The results of this retrospective medical chart review highlight unmet needs that exist for African American patients with symptomatic sarcoidosis, who are disproportionately affected by the disease, and reinforce Acthar Gel's potential to help improve health outcomes for appropriate patients,"1,4,5 said George Wan, Ph.D., M.P.H., Vice President, Evidence Generation and Data Sciences, Mallinckrodt.
  • "This research reflects Mallinckrodt's commitment to collecting real-world data on the relationship between patient characteristics, treatment patterns, and outcomes to support clinicians' treatment decisions and address disparities in symptomatic sarcoidosis care.
  • "1

Caribou Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Monday, March 11, 2024
Fast Track, Regenerative Medicine Advanced Therapy, Cancer Immunology Research, Research, CRISPR, Rachel Haurwitz, Doctor of Philosophy, Orphan drug, AML, FDA, Food, Reindeer, AACR, Manuscript, Bone marrow, Amplification, Patent, Patient, ASCT, Asian literature, Acute myeloid leukemia, G&A, IND, Insurance, Pharmaceutical industry

BERKELEY, Calif., March 11, 2024 (GLOBE NEWSWIRE) --  Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today reported financial results for the fourth quarter and full year 2023 and reviewed recent pipeline progress.

Key Points: 
  • “For our lead program, CB-010, we plan to present initial dose expansion data and the RP2D in the second quarter of 2024.
  • For our third program, CB-012, we are thrilled to have recently dosed the first patient in the AMpLify trial.
  • In December 2023, Caribou shared regulatory feedback from the U.S. Food and Drug Administration (FDA) following a Type B clinical meeting.
  • CB-012: Caribou plans to provide updates on dose escalation as the AMpLify Phase 1 clinical trial in r/r AML advances.

Zymeworks Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Wednesday, March 6, 2024
Senior, Research, Fulvestrant, Sale, University, NBI, Tax, MSAT, Plasma, CD28, BTC, NASDAQ Biotechnology Index, Pain, Rat, BLA, Standard of care, Antibody, HER2, MD Anderson Cancer Center, Abstract (summary), GAAP, Therapy, Carcinoma, Abstract, Depreciation, Partnership, Camptothecin, Manuscript, Conference, Partner, IND, NMPA, Jazz Pharmaceuticals, PFS, BeiGene, FDA, Spacecraft, Pembrolizumab, CDX, ADC, OS, Society, Patient, Pharmaceutical industry

Financial Results for the Year Ended December 31, 2023

Key Points: 
  • Financial Results for the Year Ended December 31, 2023
    Revenue was $76.0 million in 2023 compared to $412.5 million in 2022.
  • Higher interest income in 2023 was due to income earned on higher cash resources and at higher rates of return in 2023.
  • “We are happy to report a continued reduction of our operating cash burn and operating losses during 2023 compared to 2022,” said Chris Astle, Ph.D., Senior Vice President and Chief Financial Officer of Zymeworks.
  • Reconciliations between historical GAAP and non-GAAP information are contained at the end of this press release following the accompanying financial data.

NextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science Advances

Retrieved on: 
Tuesday, March 5, 2024
Nervous system, Science Advances, Immunotherapy, Spacecraft, Manuscript, ADC, Bi-specific T-cell engager, AGM, Patient, FLRT3, Cancer, Vaccine

The publication details preclinical data evaluating the role of Fibronectin Leucine-Rich Transmembrane protein-3 (FLRT3) in the inhibition of T cell activity and the use of a monoclonal antibody to reverse these effects.

Key Points: 
  • The publication details preclinical data evaluating the role of Fibronectin Leucine-Rich Transmembrane protein-3 (FLRT3) in the inhibition of T cell activity and the use of a monoclonal antibody to reverse these effects.
  • These data demonstrate that cancer cells can exploit AGM protein-protein interactions to evade T cell anti-tumor immunity by acting as checkpoint inhibitors to suppress T cell responses and immune function.
  • Future studies will dissect the roles of membrane and soluble FLRT3 on T cell signaling through UNC5B, and downstream pathways.
  • The data were generated in collaboration with Dr. David Langenau at the Massachusetts General Hospital Research Institute’s Molecular Pathology and Cancer Center.

Chimerix Reports Fourth Quarter and Year End 2023 Financial Results and Provides Operational Update

Retrieved on: 
Thursday, February 29, 2024
ONC201, MD, ASCO, Growth, Neuro-Oncology (journal), Manuscript, HGG, Conference, Human, Society, Patient, Journal, Survival, JCO, Pharmaceutical industry

DURHAM, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today reported financial results for the fourth quarter and full-year ended December 31, 2023 and provided an operational update.

Key Points: 
  • ET Today –
    DURHAM, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today reported financial results for the fourth quarter and full-year ended December 31, 2023 and provided an operational update.
  • Chimerix reported a net loss of $18.2 million, or $0.20 per basic and diluted share, for the fourth quarter of 2023, compared to a net loss of $21.0 million, or $0.24 per basic and diluted share for the fourth quarter of 2022.
  • General and administrative expenses decreased to $5.2 million for the fourth quarter of 2023, compared to $5.3 million for the same period in 2022.
  • Chimerix will host a conference call and live audio webcast to discuss fourth quarter and full-year 2023 financial results and provide a business update today at 8:30 a.m.

Alector Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, February 27, 2024
PD, GSK, Arnon Rosenthal, Investment, Interest, ARIA, AbbVie, Webcast, Plasma, PET, MRI, Central nervous system, Traffic barrier, GPNMB, Cerebrospinal fluid, Breakthrough therapy, ALEC, Frontotemporal dementia, FTD, DSM-IV codes, European Medicines Agency, Food and Drug Administration, Canadian International Council, Brain, SAN, Total, LTE, Amyloid-related imaging abnormalities, Alector, ALS, AAIC, PROGRESS, ABC, Manuscript, Conference, Safety, Biomarker, Patent, CSF, Mutation, IND, Microglia, European Patent Convention, Insurance, PIN, FDA, Food, Risk, TREM2, Dementia, Disease, Pharmaceutical industry

Alector and GSK are co-developing AL101 for the potential treatment of more prevalent neurodegenerative diseases, including AD and Parkinson’s disease.

Key Points: 
  • Alector and GSK are co-developing AL101 for the potential treatment of more prevalent neurodegenerative diseases, including AD and Parkinson’s disease.
  • In September 2023, Alector completed enrollment of 381 participants in the randomized, double-blind, placebo-controlled, dose-ranging, INVOKE-2 Phase 2 clinical trial.
  • In July 2023, Alector presented an update on INVOKE-2 at the Alzheimer’s Association International Conference (AAIC).
  • Alector’s management team will host a conference call discussing Alector’s results for the fourth quarter and full year 2023 and provide a business update.

Manuscript Discussing the Benefit of SeaStar Medical’s Selective Cytopheretic Device in Patients with Heart Failure and Hyperinflammation Published in European Journal of Heart Failure

Retrieved on: 
Tuesday, February 27, 2024
Cardiorenal syndrome, Division, Inflammation, FDA, Food, SCD, Emeritus, Manuscript, Hospital, Heart failure, European Journal, University, SeaStar, Internal medicine, Glucocorticoid, Acute kidney injury, Michigan Medicine, Drug, Monocyte, FACC, Acute respiratory distress syndrome, LVAD, Mortality, Heart, Pharmaceutical industry

DENVER, Feb. 27, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces publication of a manuscript discussing the role of chronic dysregulated systemic inflammation in heart failure and the potential application of the adult Selective Cytopheretic Device, part of the Quelimmune™ product family, in enabling previously ineligible patients with severe disease to receive a left ventricular assist device (LVAD) or heart transplant in the peer-reviewed European Journal of Heart Failure February 2024, Pitt, B., Iyer, S.P.N. and Humes, H.D. (2024), Eur J Heart Fail. https://doi.org/10.1002/ejhf.3177.

Key Points: 
  • The manuscript, titled “New Opportunity for Targeting Systemic Inflammation in Patients with Heart Failure through Leukocyte Immunomodulation” cites increasing evidence of the role of chronic systemic inflammation in patients with heart failure and discusses the Adult SCD’s potential to improve hypertensive heart failure and mortality following hospitalization for acute or worsening heart failure.
  • Following treatment with the Adult SCD, this patient was effectively bridged to LVAD three days after discontinuing treatment and was subsequently discharged without further complications.
  • “Prior attempts targeting singular proinflammatory factors as well as systemic immunosuppression with glucocorticoids in patients with acute heart failure have yielded unclear results, raising the need to identify new strategies.
  • “While our manuscript discusses a positive outcome in one patient following treatment for six hours daily over six consecutive days, the results suggest that more study with Adult SCD is warranted for patients with heart failure and hyperinflammation.”